Director's Dealing • Dec 2, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
| FORM 4 | OMB APPROVAL | |||||
|---|---|---|---|---|---|---|
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. (Print or Type Responses) |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
Estimated average burden hours per | ||||
| 1. Name and Address of Reporting Person * Mignone Roberto |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [ TEVA ] |
5. Relationship of Reporting Person(s) to Issuer | (Check all applicable) | |||
| (Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., |
(Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 11/26/2025 |
X Director Officer (give title below) |
10% Owner Other (specify below) |
(Street)
(City) (State) (Zip)
Tel Aviv, L3 6944020
OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person
| 1.Title of Security (Instr. 3) |
2. Transaction Date (Month /Day/Year) |
2A. Deemed Execution Date, if any (Month/Day /Year) |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | Amount | (A) or (D) |
Price | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
||||
| Ordinary Shares (1) | 11/26/2025 | S | 50,000 | D | \$ 26.0301 (2) | 445,000 | I | [see footnote] (3) |
||
| Ordinary Shares (1) | 105,315 | D |
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security |
3. Transaction Date (Month /Day/Year) |
3A. Deemed Execution Date, if any (Month/Day /Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially |
10. Ownership Form of Derivative Security: |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | V | (A) | (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
Owned Following Reported Transaction (s) (Instr. 4) |
Direct (D) or Indirect (I) (Instr. 4) |
| /s/ Dov Bergwerk as attorney-in-fact for Roberto Mignone 12/01/2025 | ||
|---|---|---|
| ** Signature of Reporting Person |
Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.